John Paul Murad

Assistant Professor of Research Medicine

Is this your profile? Click to edit

Publications

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment. bioRxiv. 2026 Jul 03.. View in PubMed
Focal radiotherapy improves CAR T cell therapy targeting prostate cancer. bioRxiv. 2026 Jun 24.. View in PubMed
IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer. Mol Ther Adv. 2026 Jun 11; 34(2):201730.. View in PubMed
IL12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer. bioRxiv. 2026 Mar 08.. View in PubMed
Current state of CAR-T cell therapies for solid tumors. Med. 2026 May 08; 7(5):101028.. View in PubMed
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng. 2026 Apr; 10(4):613-629.. View in PubMed
Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors. J Immunother Cancer. 2025 Aug 11; 13(8).. View in PubMed
Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery. bioRxiv. 2025 May 19.. View in PubMed
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024 06; 30(6):1636-1644.. View in PubMed
Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells. Mol Ther Oncol. 2024 Jun 20; 32(2):200789.. View in PubMed